GRACELL BIOTECHNOLOGIES-ADR (GRCL)
US38406L1035 - ADR
| MRQ (2023-6-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 1.18B | 1.45B | 1.83B | 754.30M | 312.10M | |||
| Marketable Securities | 7.60M | 6.90M | 7.70M | 22.10M | 8.20M | |||
| Receivables | 35.80M | 26.30M | 40.70M | 31.00M | 13.80M | |||
| Other Current Assets | 19.60M | 7.90M | 7.70M | 8.10M | 6.30M | |||
| Total Current Assets | 1.25B | 1.50B | 1.89B | 815.50M | 340.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 119.60M | 144.70M | 153.50M | 119.10M | 48.30M | |||
| Other Non-Current Assets | 10.90M | 15.80M | 21.60M | 30.40M | 23.50M | |||
| Total Non-Current Assets | 130.50M | 160.50M | 175.00M | 149.50M | 71.80M | |||
| TOTAL ASSETS | 1.38B | 1.66B | 2.06B | 965.00M | 412.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 92.80M | 109.30M | 66.10M | 50.00M | 0.00 | |||
| Current Portion Of LT Debt. | 13.00M | 7.80M | 2.40M | 1.00M | N/A | |||
| Accrued Expenses | 82.50M | 98.40M | 82.90M | 39.80M | 17.80M | |||
| Other Current Liabilities | 5.60M | 5.10M | 3.80M | 2.60M | 300.00K | |||
| Total Current Liabilities | 193.80M | 220.60M | 155.10M | 93.40M | 18.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 40.00M | 46.50M | 54.30M | 51.90M | 138.70M | |||
| Other Non-Current Liabilities | 7.40M | 13.40M | 23.30M | N/A | N/A | |||
| Total Non-Current Liabilities | 47.40M | 59.90M | 77.70M | 51.90M | 138.70M | |||
| TOTAL LIABILITIES | 241.20M | 280.50M | 232.80M | 145.30M | 156.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.92B | -1.63B | -1.02B | -564.00M | -289.40M | |||
| Additional Paid In Capital | 2.94B | 2.93B | 2.90B | N/A | N/A | |||
| Common Shares | 200.00K | 200.00K | 200.00K | 1.41B | 547.90M | |||
| Other Shareholders' Equity | 118.10M | 73.50M | -57.90M | -23.90M | -3.20M | |||
| Shares Outstanding | 95.77M | 95.77M | 95.62M | 92.74M | 92.74M | |||
| Tangible Book Value per Share | 3.36 | 4.06 | 5.41 | -1.79 | -0.89 | |||
| Total Shareholders' Equity | 1.14B | 1.38B | 1.83B | 819.70M | 255.40M | |||
| TOTAL LIABILITIES AND EQUITY | 1.38B | 1.66B | 2.06B | 965.00M | 412.20M | |||
| Statistics | ||||||||
| Debt/Equity | 0.12 | 0.11 | 0.07 | 0.12 | 0.54 | |||
| Current Ratio | 6.44 | 6.78 | 12.15 | 8.73 | 18.70 | |||
| Return On Assets (ROA) | -43.64% | -36.68% | -22.03% | -28.46% | -48.73% | |||
| Return On Equity (ROE) | -52.90% | -44.16% | -24.83% | -33.50% | -78.65% | |||
All data in CNY